Cargando…
Etoposide in patients with rheuma-associated hemophagocytic lymphohistiocytosis / macrophage activation syndrome
Autores principales: | Henter, Jan-Inge, Horne, AnnaCarin, Magnusson, Bo, Hagelberg, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194601/ http://dx.doi.org/10.1186/1546-0096-9-S1-P239 |
Ejemplares similares
-
How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?
por: Horne, AnnaCarin, et al.
Publicado: (2017) -
Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome
por: Schierbeck, Hanna, et al.
Publicado: (2014) -
Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome
por: Palmblad, Karin, et al.
Publicado: (2021) -
The role of etoposide in the treatment of adult patients with hemophagocytic lymphohistiocytosis
por: Zondag, Timo C. E., et al.
Publicado: (2023) -
Evaluation of immune suppressive mechanisms in a murine model of familial hemophagocytic lymphohistiocytosis
por: Humblet-Baron, Stéphanie, et al.
Publicado: (2011)